Abstract:Background Jena auf Ziel - "JaZ" - is a prospective cohort study in which early combination therapy with atorvastatin 80mg and ezetimibe 10mg was initiated on admission in all patients with ST - elevation myocardial infarction (STEMI). Lipid - lowering therapy (LLT) was escalated during follow – up with bempedoic (BA) acid and PCSK9 - inhibitors (PCSK9 - I) if serum LDL - C was not within the ESC / EAS goal of 1.4mmol/L or less. Methods and objectives We collected economic and clinical data, including in - hospital costs and length of stay. Costs related to LLT were derived from a pharmaceutical directory for Germany. Follow – ups were conducted either by the outpatient lipid clinic through scheduled appointments or through routine standard care provided by general practitioners (GPs), according to the patients' preferences. In this secondary analysis of "JaZ" we analyzed cost - effectiveness of intensive LLT therapy compared to a less effective LLT approach within the first 24 months after the index event. Results A total of 85 (85.9% men, age: 64.4 ± 13.1 years) consecutive patients were included in this study. Overall, 631 hospital days accumulated for these 85 STEMI - patients. Total cumulative costs of these stays were 802.185,13 EUR (Figure 1). 24 months after discharge, 96.3% of the patients were on statins (atorvastatin: 67.9%; rosuvastatin: 25.9%), 87.7% on ezetimibe, 17.3% on BA and 6.2% on PCSK9 - I with intermittent adjustments by the two outpatient clinics. A mean LDL - C serum reduction of 1.78 ± 1.42 mmol/L could be measured. During the 24 months of follow – up, the total costs for LLT amounted to: 35.495,78 EUR (average per case: 417,59 ± 100,49 EUR) for statins and ezetimibe; 19.983,87 EUR (average per case: 1.492,09 ± 480,97 EUR) for BA and 59.308,32 EUR (average per case: 11.861,66 ± 1.535,62 EUR) for PCSK9 - I (Figure 1). MACE occurred in 10 patients (12.3%) that required a second hospital treatment with additional costs of 73.411,17 EUR (Figure 1). Patients with MACE during follow - up exhibited a shorter duration within the target LDL - C range compared to those without MACE (58.1 ± 29.9% vs. 79.1 ± 28.1%; p < 0.05) (Figure 2). Additionally, their LDL - C levels after 24 - months were higher (2.04 ± 1.26 mmol/L vs. 1.27 ± 0.47 mmol/L; p < 0.001) (Figure 2). Patients with MACE had lower associated costs for LLT compared to patients without MACE (547.04 ± 475.93 EUR vs. 2.562,29 ± 3.170,20 EUR; p < 0.05). Incorporating the additional costs associated with MACE for the subsequent hospital stay, the overall costs for a more expensive LLT however proved to be less and thus highly cost - effective (2.562,29 ± 3.170,20 EUR vs. 7.921,25 ± 4.140,53 EUR; p < 0.01) (Figure 2). Conclusion Intensive lipid - lowering therapy within the first 24 months after STEMI is highly cost effective compared to a less effective lipid - lowering approach.

Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C

Unused potential of lipid-lowering therapy in very high-risk patients with atherosclerotic cardiovascular disease. A retrospective data analysis

Achievement of Low-Density Lipoprotein Cholesterol Targets in Chinese Patients with Atherosclerotic Cardiovascular Disease after Receiving Statins and Ezetimibe

LDL cholesterol target attainment in cardiovascular high- and very-high-risk patients with statin intolerance: a simulation study

Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia.

Evaluating the Efficacy of a Pre-Established Lipid-Lowering Algorithm in Managing Hypercholesterolemia in Patients at Very High Cardiovascular Risk

Real-world efficacy of current strategies for lowering LDL cholesterol after acute coronary syndrome. Changing the treatment paradigm

[Real-World Efficacy of Current Lipid-Lowering Strategies in Patients with Acute Coronary Syndrome. Time to Change the Paradigm for Treatment].

25 years of lipid-lowering therapy: secular trends in therapy of coronary patients

Three decades of lipid-lowering therapy in type 2 diabetic patients with angiographically proven stable coronary artery disease

Lipid management across Europe in the real-world setting: a rapid evidence review

Lipid-lowering therapy after acute coronary syndromes: a multinational European survey

LIpid Response to Statins ± Ezetimibe In Mumbai (LIRIM): A Cross-sectional Observational Study

Efficacy of lipid lowering therapy beyond statins to prevent cardiovascular events

Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: A meta-analysis of randomized controlled trials.

The Effectiveness and Safety of Intensive Lipid-Lowering with Different Rosuvastatin-Based Regimens in Patients at High Cardiovascular Disease Risk: A Nonblind, Randomized, Controlled Trial

Prevalence, incidence, and treatment of dyslipidemia in patients with high or very high cardiovascular risk in Germany

Intensive lipid - lowering therapy is highly cost effective in patients with ST - elevation myocardial infarction: a two - year follow - up of Jena auf Ziel

Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond

Lipid Management After First Diagnosis of Coronary Artery Disease: Contemporary Results From an Observational Cohort Study

Patterns and effectiveness of lipid-lowering therapies in a managed care environment